26 research outputs found

    Grape skin phenolics as inhibitors of mammalian α-glucosidase and α-amylase – effect of food matrix and processing on efficacy

    Get PDF
    Inhibition of mammalian α-amylase and α-glucosidase was studied for white grape skin samples recovered from wineries and found to be higher than that of the drug acarbose

    A Modular BAM Complex in the Outer Membrane of the α-Proteobacterium Caulobacter crescentus

    Get PDF
    Mitochondria are organelles derived from an intracellular α-proteobacterium. The biogenesis of mitochondria relies on the assembly of β-barrel proteins into the mitochondrial outer membrane, a process inherited from the bacterial ancestor. Caulobacter crescentus is an α-proteobacterium, and the BAM (β-barrel assembly machinery) complex was purified and characterized from this model organism. Like the mitochondrial sorting and assembly machinery complex, we find the BAM complex to be modular in nature. A ∼150 kDa core BAM complex containing BamA, BamB, BamD, and BamE associates with additional modules in the outer membrane. One of these modules, Pal, is a lipoprotein that provides a means for anchorage to the peptidoglycan layer of the cell wall. We suggest the modular design of the BAM complex facilitates access to substrates from the protein translocase in the inner membrane

    Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

    Get PDF
    IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

    <i style="mso-bidi-font-style:normal"><span style="font-size:15.0pt; mso-bidi-font-size:11.0pt;mso-bidi-font-family:"Times New Roman";color:black; font-weight:normal;mso-bidi-font-weight:bold" lang="EN-US">In vitro</span></i><span style="font-size:15.0pt;mso-bidi-font-size:11.0pt;mso-bidi-font-family: "Times New Roman";color:black;font-weight:normal;mso-bidi-font-weight:bold" lang="EN-US"> propagation of <i style="mso-bidi-font-style:normal">Rivina humilis</i> L. through proliferation of axillary shoots and shoot tips of mature plants </span>

    No full text
    481-485<span style="font-size:9.0pt; mso-bidi-font-size:11.0pt;mso-bidi-font-family:" times="" new="" roman";color:black;="" font-weight:normal;mso-bidi-font-weight:bold"="" lang="EN-US">In vitro <span style="font-size:9.0pt;mso-bidi-font-size:11.0pt;mso-bidi-font-family: " times="" new="" roman";color:black;font-weight:normal;mso-bidi-font-weight:bold"="" lang="EN-US">propagation of Rivina humilis L. was attempted through proliferation of axillary shoots and shoot tips obtained from mature plants. The shoot tips and nodal shoot segments exhibited 70 and 80% shoot initiation when cultured on Murashige and Skoog (MS) basal medium supplemented with 4.44 µM 6-benzylaminopurine (BAP)+2.85 µM indole-3-acetic acid (IAA) and 8.88 µM BAP+2.68 µM naphthalene acetic acid (NAA), respectively. Shoots (2 to 3) were obtained from both shoot tip and nodal explants on MS medium supplemented with BAP (2.22 µ<i style="mso-bidi-font-style: normal">M), IAA (2.85 µM) and silver nitrate (4 <span style="font-size:9.0pt;mso-bidi-font-size: 11.0pt;font-family:Symbol;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" "times="" roman";mso-bidi-font-family:"times="" roman";color:black;="" mso-char-type:symbol;mso-symbol-font-family:symbol;font-weight:normal;="" mso-bidi-font-weight:bold"="" lang="EN-US">mM<span style="font-size:9.0pt;mso-bidi-font-size:11.0pt;mso-bidi-font-family: " times="" new="" roman";color:black;font-weight:normal;mso-bidi-font-weight:bold"="" lang="EN-US"> AgNO3). Multiplication was maximum on MS medium supplemented with BAP (8.88 µM), IAA (2.85 µM) and AgNO3 (4 <span style="font-size:9.0pt;mso-bidi-font-size:11.0pt; font-family:Symbol;mso-ascii-font-family:" times="" new="" roman";mso-hansi-font-family:="" "times="" roman";mso-bidi-font-family:"times="" roman";color:black;="" mso-char-type:symbol;mso-symbol-font-family:symbol;font-weight:normal;="" mso-bidi-font-weight:bold"="" lang="EN-US">mM<span style="font-size:9.0pt;mso-bidi-font-size:11.0pt;mso-bidi-font-family: " times="" new="" roman";color:black;font-weight:normal;mso-bidi-font-weight:bold"="" lang="EN-US">) wherein 3-4 shoots per nodal explant were obtained. Microshoot elongation was achieved on MS medium containing BAP (2.22 µM) and gibberellic acid (2.89 µM GA3). Shoots (3-4 cm) exhibited 100% rooting within 4 wk in medium containing half MS with IAA (2.85-5.71 µM) or IBA (2.45-4.90 µM) alone or in combination with BAP (2.22 µM), resulting in simultaneous rooting and shoot growth. About 70% of micropropagated plants were established successfully in micropots and transferred to the field after 3 months. </span

    Tuning Physical Properties of Tomato Puree by Fortification with Grape Skin Antioxidant Dietary Fiber

    Get PDF
    Grape skins recovered from winemaking by-products were investigated for use as sustainable, antioxidant fiber-rich ingredient for the innovation of low-energy dense tomato puree. Six tomato purees fortified with grape skin antioxidant fiber, with varying particle size distribution, and two control tomato purees were studied. Physical parameters of purees were analyzed upon mixing and either an intensive heat treatment or an optimized heat treatment designed to achieve six decimal reductions of a target microorganism (Alicyclobacillus acidoterrestris) as recommended for pasteurization of acidic fruit products. Mixing of grape skin antioxidant fiber with tomato purees led to a decrease in both surface-weighted mean diameter (Sauter mean diameter, d(3,2)) and volume-weighted mean diameter (d(4,3)) values and an increase in span. Changes in these descriptors were most significant in purees added with the smallest particle sizes. Thermal stabilization of purees slightly decreased the d(3,2) values further and increased d(4,3) values, suggesting concomitant occurrence of particle disaggregation and formation of flocs within the food matrix. Phenolic solubility was inversely correlated to d(3,2) values. Bostwick consistency, storage (G\u2032) and loss (G\u2033) moduli, and complex viscosity (\u3b7*) increased in the fortified purees. The \u3b7* values displayed a positive correlation with d(4,3) values. Variations in Hunter colorimetric parameters were within the acceptability threshold. Overall, the information obtained provides knowledge to assist development of fiber-rich, low-energy dense fruit purees

    Modelling the stability of maltodextrin-encapsulated grape skin phenolics used as a new ingredient in apple puree

    No full text
    Highly soluble maltodextrin-encapsulated grape skin phenolics comprising anthocyanins and less hydrophilic flavonoids were added as an ingredient to apple puree. Upon formulation, heat treatments were applied to achieve 3-14 decimal reductions (D) of the target microorganism (Alicyclobacillus acidoterrestris). A storage study was performed at 15-35\ub0C for 1 month. Monomeric anthocyanins were retained at 100% after the 3 D treatment, while anthocyanin retention decreased to 72% with increasing heating intensity until 14 D. During storage, the concentration of monomeric anthocyanins decreased following first-order kinetics (k25 \ub0C = 34.4 d-1, activation energy = 51.0 kJ/mol). The flavanols were more stable than the monomeric anthocyanins. The hydroxycinnamic acid, dihydrochalcone and flavonol contents did not change. The fortified puree had a two-fold higher reducing capacity with respect to apple puree. Overall, this ingredient could meet the industrial demand for sustainable colouring agents and health promoting compounds

    Metabolomic Based Approach to Identify Biomarkers of Apple Intake

    No full text
    SCOPE:There is an increased interest in developing biomarkers of food intake to address some of the limitations associated with self-reported data. The objective was to identify biomarkers of apple intake, examine dose-response relationships and agreement with self-reported data. METHODS AND RESULTS:Metabolomic data from three studies were examined: an acute intervention, a short-term intervention and a free-living cohort study. Fasting and postprandial urine samples were collected for analysis by 1 H-NMR and LC-MS. Calibration curves were developed to determine apple intake and classify individuals into categories of intake. Multivariate analysis of data revealed that levels of multiple metabolites increased significantly post-apple consumption, compared to the control food- broccoli. In the dose-response study, urinary xylose, epicatechin sulfate and 2, 6-dimethyl-2-(2-hydroxyethyl)-3,4-dihydro-2H-1-benzopyran increased as apple intake increased. Urinary xylose concentrations in a free-living cohort performed poorly at an individual level but were capable of ranking individuals in categories of intake. CONCLUSION:Urinary xylose exhibited a dose-response relationship with apple intake and performed well as a ranking biomarker in the population study. Other potential biomarkers were identified and future work will combine these with xylose in a biomarker panel which may allow for a more objective determination of individual intake.European Commission Horizon 202
    corecore